Aurobindo Pharma's Subsidiary Receives GMP From European Medicines Agency For Biosimilars Facility
CuraTeQ Biologics Pvt., an Aurobindo Pharma subsidiary, was given a Good Manufacturing Practice certificate of compliance for its biosimilars manufacturing facility from the European Medicines Association on Tuesday.
"The EU GMP certification marks a significant milestone in CuraTeQ's commitment to manufacturing high-quality biosimilars for patients worldwide. This inspection outcome paves way for securing approvals for our three biosimilars in Europe, currently under review by the Agency, within the next two to five months." Satakarni Makkapati, director of Aurobindo Pharma Ltd. and chief executive officer of biologics, vaccines, and peptides, stated.
The GMP inspection was conducted by EMA representatives from April 8 to April 12, 2024.
It evaluated mammalian and microbial drug substance manufacturing facility sections, prefilled syringes and vials filling, packaging, and quality control testing and release laboratories.
"Our portfolio comprises fourteen biosimilars in development across oncology and immunology segments. We are dedicated to building a sustainable biosimilars portfolio and bringing these essential therapies to patients," Mr. K. Nithyananda Reddy, vice chairman and managing director of Aurobindo Pharma Ltd., added.
Aurobindo Pharma Ltd. reported an 8% year-on-year increase in its second-quarter profit, reaching Rs 817 crore for the quarter ending Sept. 30, 2024. However, the result fell short of analysts' expectations, with the consensus estimate pegged at Rs 972 crore, according to data from Bloomberg.
Shares of Aurobindo Pharma Ltd. closed 2.41 % lower at Rs 1 apiece on the NSE, compared to a 1.07% lower in the benchmark Nifty 50.
The stock had 16.92% on a year-to-date basis and 29.37% over the past 12 months.
The stock had an intraday low of 2.41% at Rs 1,258 per share.
Out of the 29 analysts tracking the company, 20 have a 'buy' rating on the stock, five suggest a 'hold' and four recommend 'sell', according to Bloomberg data.
The average of 12-month analysts' consensus price targets implies a potential upside of 22.5%.
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.